Harrow has announced an initiative to expand access and affordability for its ophthalmic pharmaceutical products. This includes a program of targeted price reductions for several Harrow products and a ...

Gregg T. Kokame, MD, MMM, FASRS, is set to share data from a predefined subgroup of the sozinibercept Phase 2b wet AMD trial related to patients with polypoidal choroidal vasculopathy (PCV), measured ...

LUNA is an ongoing double-masked, randomized Phase 2 trial. OPTIC is an ongoing, open-label, dose-ranging first-in-human trial. Laurent Fischer, MD, president and chief executive officer of Adverum ...

ARVN001 is indicated for the treatment of uveitic macular edema (UME) and certain other ophthalmic indications under development. Arctic Vision has signed a new commercial collaboration agreement with ...

Inflammasome Therapeutics has completed enrollment of a Phase I PK/Safety study of its new brain- and retina-penetrant drug, K9.

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field. The European Society of Retina Specialists (Euretina) held its 24th annual congress in ...

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating significant potential for the treatment option. Ocugen Inc. announced positive ...

This year’s Barcelona meeting brought together award-winning research findings and leaders in the retina field. Ian C. Han, MD, shares his thoughts on the value of anecdotal evidence in our winter ...

The FDA comments in the CRL relate to proposed labelling language, not safety, Astellas said in a press release.

Like many, I was privileged to attend the annual American Academy of Ophthalmology (AAO) meeting in Chicago, Illinois, in October. As an educator, a highlight is always hearing updates from former ...

FYB203 has been recommended by the CHMP for approval in Europe for treating adult patients with age-related neovascular macular degeneration (nAMD) and other serious retinal diseases. The Committee ...